Industry coverage tracks the money around peptides: Eli Lilly and Novo Nordisk earnings, pipeline shifts, M&A, IPOs, peptide CDMO capacity, and the telehealth and pharmacy economy that GLP-1s built.
The two stories that keep moving the most market cap: how fast oral GLP-1s reach approval (orforglipron, oral semaglutide, oral wegovy, danuglipron's exit), and what happens to the compounded-peptide channel as the FDA tightens. Hims, Ro, LifeMD, GoodRx, and Amazon Pharmacy have all rerouted distribution in the past year. Behind them, contract manufacturers like Bachem, PolyPeptide, and BASF have been the bottleneck no one talked about until they were.
Stories here name the company, the deal, and the dollars. Earnings, partnership, regulatory hit — whatever moved the share price gets covered.
Hims & Hers' announced $1.15 billion acquisition of Eucalyptus continues to be a major catalyst for the company alongside Friday's JPMorgan Overweight upgrade. Eucalyptus brings Australia and Japan exposure, with management targeting more than $1 billion in annual international revenue within three years. Combined with the recent Eli Lilly LillyDirect partnership (Foundayo, Zepbound, KwikPen) and the FDA peptide reclassification framework, Hims now has three strategic catalysts reshaping its 2026 trajectory.
Hims & Hers announced April 23 a strategic expansion of its U.S. weight loss platform, adding licensed-provider prescriptions for Eli Lilly's Zepbound vials, Zepbound KwikPen, and Foundayo. Prescriptions are fulfilled through LillyDirect pharmacy, completing a dual-supplier arrangement after last month's Novo Nordisk Wegovy collaboration. Shares jumped roughly 7% on the announcement as investors digested the company's pivot from compounded GLP-1s toward branded distribution.
JPMorgan initiated coverage of Hims & Hers on April 24 with an Overweight (Buy-equivalent) rating and a $35 price target, citing the Novo Nordisk and Eli Lilly partnerships, progress toward peptide legalization, and a likely revenue rebound in H2 2026. Shares jumped about 9.6% intraday Friday, representing roughly 25% upside from Thursday's close. The note specifically called out the Novo Nordisk deal as 'a turning point' that resolves the company's prior legal overhang from compounded GLP-1 production.
Cerapedics, Inc. announced April 24 a supplier agreement with Vizient for PearlMatrix® P-15 Peptide Enhanced Bone Graft, a Class III drug-device combination product for adult patients with degenerative disc disease in the lumbar spine. The deal extends access to Vizient's network of academic medical centers, community hospitals, and integrated health delivery networks. PearlMatrix uses a 15-amino-acid peptide (a fragment of Type I collagen) bound to anorganic bone mineral as a bone growth accelerator — one of the few peptide-enhanced devices on the U.S. orthopedics market.
A Drug Discovery News feature surveyed the emerging hair loss treatment landscape and asked whether the category could replicate the GLP-1 obesity drug breakout. Lead candidates include Pelage Pharmaceuticals' PP405 (small-molecule topical, Phase 3 launch 2026 with FDA approval potentially 2027-2029), the MLPH peptide (preclinical, novel safe mechanism for both sexes), the APN5 peptide (Korean research team, hair growth + suppression of loss), and product launches from Ouai Haircare's $50 Bond Repair Balm and Omi Well Beauty's Hair Growth Peptides expanding the consumer category.
Roche reported Q1 2026 sales up 6% at constant exchange rates and used the earnings call to re-anchor its obesity strategy. Executives project $9 billion in peak annual sales from the emerging breast cancer pill plus four obesity candidates. Lead asset petrelintide (licensed from Zealand Pharma, ZUPREME-1 Phase 2 showed up to 10.7% weight loss with placebo-like tolerability) is positioned at a differentiated patient segment. CEO Schinecker said Roche is not investing in the first generation of obesity drugs, but the next — with petrelintide and CT-388 (enicepatide) data headed for ADA 2026.
Eli Lilly shares fell April 24 after the latest weekly prescription data for Foundayo showed 3,707 scripts for the week ending April 17 — behind analyst expectations. For comparison, Novo's Wegovy pill reached 18,410 prescriptions in its second week after a January launch. RBC Capital Markets analyst Trung Huynh said early comparisons should be viewed cautiously but acknowledged the uptake is 'likely to be received negatively.' Fierce Pharma launched a weekly Oral GLP-1 Tracker to follow Foundayo and Wegovy pill head-to-head.
Clean luxury skincare brand SVEDA launched its Renewal Peptide Serum ($124.99) on April 24. The formulation pairs caviar extract and hydrolyzed pearl (providing amino acids and trace minerals supporting collagen synthesis) with bakuchiol (a plant-derived retinol alternative), green tea hydrosol, Tsubaki seed oil, and grass-fed beef tallow. The launch lands in a broader consumer-peptide boom — 'peptide therapy' search interest is up 281% YoY on Google, 459% on TikTok, and 412% on Instagram as cosmetic brands rush to capture the mainstreaming trend.
Ahead of Amgen's April 30 Q1 2026 earnings release, analyst coverage highlighted MariTide as the company's most closely-watched pipeline asset. The bispecific GLP-1 RA / GIPR antagonist delivered up to 20% weight loss at 52 weeks in Phase 2 and is now enrolled across six global Phase 3 trials — with monthly, bi-monthly, and potentially quarterly dosing as its primary commercial differentiator against weekly GLP-1s. Amgen recorded $35.1 billion in 2025 product sales (+10%), and MariTide headline data from the Phase 3 program is expected to begin reading out in 2027.
MBX Biosciences announced an April 23 press release confirming its May 11 virtual Obesity Day event, at which the company will formally update investors on its Precision Endocrine Peptide (PEP) platform. The portfolio includes MBX 4291 (Phase 1 GLP-1/GIP co-agonist prodrug designed for once-monthly dosing), an amycretin prodrug with Q2 2026 nomination expected, and a GLP-1/GIP/GCGR triple agonist prodrug with Q3 2026 nomination — all targeting once-monthly administration. Richard DiMarchi and Katherine Saunders will headline the event.
Canadian-listed The Precision Peptide Company (CSE:BPC) announced April 23 a six-month strategic product marketing agreement with UK-based creative agency Raw Creation for CAD$85,500 total (CAD$9,000 setup plus CAD$76,500 retainer), rolling to CAD$15,000/month afterward. The deal covers social media management, creative and video production, editorial and press services, and paid advertising — an early indicator that small-cap peptide-focused companies are investing in consumer marketing infrastructure as the category enters mainstream awareness.
The AACR Annual Meeting 2026 concluded April 22 in San Diego after six days featuring unprecedented peptide-oncology visibility. Macrocyclic peptide drug conjugate (PDC) pipelines across Circle Pharma, Bicycle Therapeutics, Oncopeptides, and SignaBlok drew regulatory and venture attention; peptide-targeting radioligand data from Perspective Therapeutics, Bicycle, and AlphaGen signaled maturation of the peptide-radioconjugate subcategory. AACR Advances sessions throughout the meeting featured targeted protein degradation and novel tumor-selective modalities, with peptide-based approaches competing directly with antibody drug conjugates in Phase 1/2 readouts.
Swiss peptide CDMO Bachem announced a strategic partnership and asset acquisition in April 2026 to scale large-scale peptide API production. The move responds to surging demand for GLP-1 and next-generation peptide drugs — the global peptide synthesis market is now projected to reach $2.26 billion by 2033 at an 11.4% CAGR. Bachem previously secured a CHF 1 billion peptide supply contract and is operating three site expansions to address capacity constraints that have periodically disrupted semaglutide and tirzepatide supply.
Eli Lilly shares closed down nearly 2% at $918.56 and Novo Nordisk fell ~4% on April 22 after CVS Health's decision to opt out of the Medicare obesity drug coverage pilot triggered CMS to scrap the BALANCE model. The combined market cap loss across the two GLP-1 leaders exceeded $25 billion. Hims & Hers dropped another 6% on continued Amazon One Medical competitive pressure.
Telehealth rival Hims & Hers Health shares slid 6% April 21-22 after Amazon's One Medical launched a comprehensive GLP-1 weight management program offering Wegovy and Foundayo starting at $25/month with insurance or $149/month cash-pay for oral options. The move positions Amazon against established telehealth obesity care providers (Hims, Ro, LifeMD, Noom) as the compounded-GLP-1 era winds down.
Amazon One Medical launched a nationwide GLP-1 Management Program offering Wegovy, Zepbound, and Lilly's Foundayo starting at $25/month with insurance, plus $149/month cash-pay for oral drugs and $299/month for injectables. Same-day delivery in nearly 3,000 cities, expanding to 4,500 by year-end. Shares of Eli Lilly, Novo Nordisk, and Hims & Hers fell on the news.
Obesity biotech Kailera Therapeutics priced an upsized IPO of 39.06 million shares at $16, raising $625 million — the largest venture-backed biopharmaceutical IPO since Acelyrin in 2023. Lead candidate ribupatide (a GLP-1/GIP peptide dual agonist) drove 18% body weight loss at 48 weeks in a late-stage Chinese study; global Phase 3 readout expected in 2028.
A new market landscape report published April 21 projects the global peptide drug conjugate market will exceed $1.5 billion by 2031, with >14% CAGR and coverage of more than 50 peptide conjugates currently in clinical development. Commercial PDC benchmarks include Novartis's Lutathera and Pluvicto and Bicycle Therapeutics' nuzefatide pevedotin, with earlier-stage pipelines from Zymeworks, Bicycle, PeptiDream, and others.